Kerry Group to Acquire Lactase Enzyme Business from Chr. Hansen and Novozymes

Novozymes and Chr. Hansen Combine to Form Novonesis

January 29, 2024

Biotechnology

On January 29, 2024 Novozymes and Chr. Hansen completed a statutory merger to create Novonesis, a global biosolutions company focused on enzymes, cultures and microbial solutions. The combined group will employ around 10,000 people worldwide and have pro forma annual revenue of approximately EUR 3.7 billion, with targeted synergies across food & health and planetary health portfolios.

Chr. Hansen Acquires UAS Laboratories LLC

June 9, 2020

Biotechnology

Chr. Hansen Holding A/S has agreed to acquire 100% of UAS Laboratories LLC from Lakeview Equity Partners, the UAS management team and other shareholders for USD 530 million (net of tax assets). The acquisition (UAS Labs: ~230 employees, ~USD 85m revenue and >USD 30m EBITDA in 2020) strengthens Chr. Hansen’s microbial platform and Human Health business by adding probiotic strains, two GMP production facilities in Wisconsin, and increased fermentation and downstream processing capacity.

Kerry Group Acquires Majority Stake in c-LEcta GmbH

February 15, 2022

Biotechnology

Kerry Group reached an agreement to acquire a majority shareholding in enzyme engineering and bioprocess development company c-LEcta GmbH. The deal is intended to accelerate Kerry’s innovation capabilities in enzyme engineering and fermentation while helping c-LEcta expand into new food and pharmaceutical markets.

Kemin Industries Acquires CJ Youtell Biotech

September 23, 2025

Biotechnology

Kemin Industries has acquired CJ Youtell Biotech, the enzymes and fermentation subsidiary of CJ Bio, gaining full ownership of CJ Youtell’s fermentation plants and enzyme product portfolio. The acquisition adds fermentation capacity in Shandong and Hunan, China and expands Kemin’s global enzyme R&D, manufacturing and product offerings across animal feed, food, aquaculture and industrial end markets.

BioMarin Pharmaceutical Completes Acquisition of Inozyme Pharma

May 16, 2025

Healthcare Services

BioMarin Pharmaceutical Inc. completed its all-cash acquisition of Inozyme Pharma, Inc. for $4.00 per share, valuing the deal at approximately $270 million. The transaction adds INZ-701, a late-stage enzyme replacement therapy being developed for ENPP1 Deficiency, to BioMarin’s enzyme therapies portfolio.

Kerry Group Acquires Niacet for $1.015B

June 21, 2021

Food & Beverage

SK Capital’s affiliate agreed to sell Niacet Corp. to Kerry Group plc for $1.015 billion on a cash-free, debt-free basis, subject to customary closing adjustments. Niacet will be integrated into Kerry’s global food protection and preservation platform, and the deal was expected to close by the end of Q3 2021 pending approvals.